The mechanism of action of imiquimod 5% cream applied topically to patients with genital
warts was evaluated in a double-blind, placebo-controlled study. Imiquimod (16 patients) or …

Genital human papillomavirus infection is one of the most common sexually transmitted
diseases. Imiquimod is a new agent, an immune-response modifier, that has been …

Imiquimod is a topically active immunomodulatory agent that is formulated as a 5% cream
for application by the patient. It is the first agent of its class, the immune response modifiers …

Background: Genital warts are a common sexually transmitted disease caused by human
papillomavirus. Imiquimod is a novel immune-response modifier capable of inducing a …

Imiquimod is a novel synthetic molecule with potent immune-modifying activities. Formulated
in a 5% vanishing cream as Aldara™, this self-applied therapy has shown good efficacy and …

Objective: The purpose of this double-blind, placebo-controlled study was to evaluate the
safety, clinical efficacy and tole-rability of imiquimod (2%) in cream to cure external genital …

The purpose of this randomized, double‐blind, placebo‐controlled study was to determine
the clinical efficacy and tolerability of an analog of imiquimod (2%) in cream to cure genital …

Objective: To assess the safety of imiquimod, an immune response modifier, in the topical
treatment of external anogenital warts in HIV-infected patients. Setting: Clinical sites in the …

Background Medical therapy for genital warts remains suboptimal. The topical interferon and
cytokine inducer, imiquimod, has been proved effective for the treatment of external genital …

Our objective was to determine the optimal duration of treatment with imiquimod for external
genital warts over 4, 8, 12 or 16 weeks. A total of 120 women with a history of genital warts …